Nice approves rimegepant for preventing migraines in cases where at least three previous treatments have failed
Thousands of people in England who get migraines could benefit from a drug that has been approved on the NHS.
The National Institute for Health and Care Excellence (Nice), the drugs regulator, said it was recommending rimegepant for preventing migraines in the approximately 145,000 adults where at least three previous preventive treatments had failed.
More Stories
23andMe’s founder wins bid to regain control of bankrupt DNA testing firm
DNA testing firm 23andMe fined £2.3m by UK regulator for 2023 data hack
Key crop yields could fall due to climate crisis even if farmers adapt, study finds